Divi's Laboratories Limited

Total Valuation

Divi's Laboratories Limited carries a market capitalization of 1.82T, placing it among publicly traded companies globally. Its enterprise value stands at 1.81T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Divi's Laboratories Limited trades at a trailing price-to-earnings ratio of 78.46.

Enterprise Valuation

On an enterprise value basis, Divi's Laboratories Limited trades at an EV/EBITDA multiple of 68.09 and an EV/FCF ratio of 47,780.77. The EV/Sales ratio of 18.74 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 68.09 provides insight into valuation relative to core operating earnings.

Financial Position

Divi's Laboratories Limited maintains a current ratio of 14.18, meaning it holds 14.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.09, indicating conservative leverage, while an interest coverage ratio of 531.40 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Divi's Laboratories Limited has paid 7.39B in income taxes, reflecting an effective tax rate of 24.27.

Stock Price Statistics

Divi's Laboratories Limited's stock has declined approximately -0.46781926% over the past 52 weeks. The 50-day moving average sits at 6,682.11, while the 200-day moving average is 6,380.95.

Income Statement

Over the trailing twelve months, Divi's Laboratories Limited generated 96.52B in revenue and converted that into 23.06B in net income, yielding earnings per share of 86.82. EBITDA reached 26.57B, while operating income came in at 26.57B.

Margins

Divi's Laboratories Limited operates with a gross margin of 60.34, reflecting its pricing power and cost economics. The operating margin of 27.53 and net profit margin of 23.89 provide insight into operational efficiency.

Stock Splits

Divi's Laboratories Limited's most recent stock split took place on September 23, 2015 with a 1:2 split ratio.

Scores

Divi's Laboratories Limited posts an Altman Z-Score of 97.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.